Accueil   Diary - News   All news Orphanse Healthcare

Orphanse Healthcare




Lyonbiopole's member ORPHANSE HEALTHCARE, develops alternative solutions to pharmaceutical intravenous administration.

The necessity of administering medicine to efficiency of immediate share is a daily reality of the patients management in medicine. The reference way of administration is intravenous.


It was shown that the insertion of a peripheral venous access presents heavy inconveniences.


The provision of a not invasive way of administration, enabling bioavailability of the same drug that achieved by IV administration, is a major issue.

For the development of therapeutic solutions, Healthcare Orphanse combines many original factors:


 • An original way of administration (buccal way)
• A new patented pharmaceutical formulation
• An industrialized delivery device, simple and inexpensive
• Molecules estimated by doctors and known by regulators.

Orphanse Healthcare innovates by offering advanced on all the following essential criteria:


• A therapeutic efficacy at least equivalent to the IV way
• A safety increased use
• A simplicity implementation
• An  patient acceptability improvement
• A positive economic impact for the payer.


Technological Orphanse combination of interest in the "universe" various medical (medical emergency, pediatrics, emergency preparedness (CBRN risks), access to care in emerging countries).

First development carry on hospital analgesic and treatment of an infectious disease of viral origin.